Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 18

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 1
Chunk 18
---
ologic variants as well as neoantigens across the exome from tissue samples, thus enabling IO applications

    •Run at ~150-250x media coverage for approximately 650 of the most significant onco-driving mutations and ~150-200x median coverage for more than 19,000genes on the panel

    •Detects TMB, MSI, and fusions

    Tempus|xF
    2018
    •Next-generation liquid biopsy assay covering 105 genes at approximately 20,000x coverage from peripheral blood samples for solid tumors

    •Typically used for oncogenic and resistance mutations that can be detected in cell free DNA, or cfDNA, from a peripheral blood draw

    •In our analytical validation, for 0.5% VAF and 30ng of DNA, we demonstrated >99.9% sensitivity for SNVs, 98.8% for indels, >99.9% for CNVs, and 97.4% for rearrangements and fusions. xF also demonstrated 100% sensitivity concordance with Roche AVENIO ctDNA Expanded Kit for indels, CNVs, and rearrangements. We also demonstrated >99.9% specificity for SNVs, indels, and fusions, and 96.2% specificity for CNVs

    Tempus|xG
    2021
    •The xF+ version is a 523 gene panel that includes bTMB, MSI, additional fusions and CNVs•52 gene inherited cancer germline panel run off whole exome platform at 75x depth of coverage

    •Tests hereditary predisposition across common and well- described cancer syndromes such as breast, ovarian, prostate cancer (BRCA1, BRCA2), pancreatic cancer (CDKN2A, PALB2), colorectal cancer (APC, BMPR1A), and Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) 

    •Typically used in patients with a personal and / or family history suggestive of hereditary predisposition to cancer and can guide future diagnostic decisions

    •The xG+ version is an 88 gene panel covering genes associated with both 

22

    Lab Tests 
    Launch Year
    Description

    common and rare hereditary cancers

    Tempus|xR
    2023
    •Full transcriptomic profiling assay for solid tumors and